Cargando…

Identification of potential therapeutic targets in prostate cancer through a cross‐species approach

Genetically engineered mouse models of cancer can be used to filter genome‐wide expression datasets generated from human tumours and to identify gene expression alterations that are functionally important to cancer development and progression. In this study, we have generated RNAseq data from tumour...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jurmeister, Sarah, Ramos‐Montoya, Antonio, Sandi, Chiranjeevi, Pértega‐Gomes, Nelma, Wadhwa, Karan, Lamb, Alastair D, Dunning, Mark J, Attig, Jan, Carroll, Jason S, Fryer, Lee GD, Felisbino, Sérgio L, Neal, David E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840539/ https://www.ncbi.nlm.nih.gov/pubmed/29437778 http://dx.doi.org/10.15252/emmm.201708274

Ejemplares similares

A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy
por: Pertega‐Gomes, Nelma, et al.
Publicado: (2015)

A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer
por: Pértega-Gomes, Nelma, et al.
Publicado: (2014)

Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer
por: Pertega-Gomes, Nelma, et al.
Publicado: (2015)

Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells
por: Jurmeister, Sarah, et al.
Publicado: (2014)

Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
por: Pértega-Gomes, Nelma, et al.
Publicado: (2014)

Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer
por: Barquilha, Caroline N., et al.
Publicado: (2020)

Clinical impact of the metabolic phenotype of prostate cancer: role of monocarboxylate transporters (MCTs)
por: Pértega-Gomes, Nelma, et al.
Publicado: (2013)

Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer
por: Valença, Isabel, et al.
Publicado: (2015)

Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer
por: Pinto, Filipe, et al.
Publicado: (2016)

Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer
por: Hori, Satoshi, et al.
Publicado: (2017)

Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer
por: Pértega-Gomes, Nelma, et al.
Publicado: (2011)

HES5 silencing is an early and recurrent change in prostate tumourigenesis
por: Massie, Charles E, et al.
Publicado: (2015)

Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer
por: Zecchini, Vincent, et al.
Publicado: (2014)

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network
por: Ramos-Montoya, Antonio, et al.
Publicado: (2014)

Undernutrition in utero increases susceptibility to prostate neoplasias in adult rat after steroid exposure
por: Rinaldi, Jaqueline C, et al.
Publicado: (2013)

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target
por: Asim, Mohammad, et al.
Publicado: (2015)

Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy
por: Sandi, Chiranjeevi, et al.
Publicado: (2013)

Epigenetic-based therapies for Friedreich ataxia
por: Sandi, Chiranjeevi, et al.
Publicado: (2014)

Mining Human Prostate Cancer Datasets: The “camcAPP” Shiny App()
por: Dunning, Mark J., et al.
Publicado: (2017)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

MutLα Heterodimers Modify the Molecular Phenotype of Friedreich Ataxia
por: Ezzatizadeh, Vahid, et al.
Publicado: (2014)

The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer
por: Sharma, Naomi L., et al.
Publicado: (2014)

Cellular, Molecular and Functional Characterisation of YAC Transgenic Mouse Models of Friedreich Ataxia
por: Anjomani Virmouni, Sara, et al.
Publicado: (2014)

Friedreich Ataxia Patient Tissues Exhibit Increased 5-Hydroxymethylcytosine Modification and Decreased CTCF Binding at the FXN Locus
por: Al-Mahdawi, Sahar, et al.
Publicado: (2013)

Generation and Characterisation of Friedreich Ataxia YG8R Mouse Fibroblast and Neural Stem Cell Models
por: Sandi, Chiranjeevi, et al.
Publicado: (2014)

A novel GAA-repeat-expansion-based mouse model of Friedreich’s ataxia
por: Anjomani Virmouni, Sara, et al.
Publicado: (2015)

Structural and ultrastructural evidence for telocytes in prostate stroma
por: Corradi, Lara S, et al.
Publicado: (2013)

Prostate Cancer Secretome and Membrane Proteome from Pten Conditional Knockout Mice Identify Potential Biomarkers for Disease Progression
por: Santos, Nilton J., et al.
Publicado: (2022)

Updates of prostate cancer staging: Prostate-specific membrane antigen
por: Sathianathen, Niranjan J, et al.
Publicado: (2016)

Finasteride Inhibits Human Prostate Cancer Cell Invasion through MMP2 and MMP9 Downregulation
por: Moroz, Andrei, et al.
Publicado: (2013)

Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype
por: Robinson, Jessica L.L., et al.
Publicado: (2013)

Identification of telomere dysfunction in Friedreich ataxia
por: Anjomani Virmouni, Sara, et al.
Publicado: (2015)

Pharmacological Screening Using an FXN-EGFP Cellular Genomic Reporter Assay for the Therapy of Friedreich Ataxia
por: Li, Lingli, et al.
Publicado: (2013)

Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study
por: Ross-Adams, H., et al.
Publicado: (2015)

“Prostate telocytes change their phenotype in response to castration or testosterone replacement”
por: Felisbino, Sérgio Luis, et al.
Publicado: (2019)

Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer
por: Santos, Nilton José, et al.
Publicado: (2021)

The provision of prostate cancer patient information leaflets on an electronic tablet: A further step to paperless health-care provision
por: Miah, Saiful, et al.
Publicado: (2022)

Fibronectin Modulates the Expression of miRNAs in Prostate Cancer Cell Lines
por: Martinucci, Bruno, et al.
Publicado: (2022)

Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression
por: Fonseca-Alves, Carlos Eduardo, et al.
Publicado: (2018)

Transperineal prostate biopsies for diagnosis of prostate cancer are well tolerated: a prospective study using patient-reported outcome measures
por: Wadhwa, Karan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e7a2pkqav3pbcqqso116mhp1ro